TSXV:BTI.H - Post by User
Comment by
chrispion Mar 23, 2021 10:18am
185 Views
Post# 32857493
RE: RE: BTI kicks the warrant can down the road, reduces price
RE: RE: BTI kicks the warrant can down the road, reduces priceCome on digitel, you can do better than that.
Heading into the end of month and the potential expiry of the Prothena options ==> read JD's great post about this over here there is no mention of Stern IR at the bottom of the news release or anyone other than Rathjen. ==> why would you be expecting to see anyone else mentioned besides Rathjen, especially just for a PR announcing an extension of warrants? Who else needs to be mentioned on it? Almost all of the company PRs just have the current CEO (or similiar) listed as the company person. You can go to the company website to find the full directory of their - Leadership Team
- Board of Directors
- Medical Advisory Board
- Scientific Advisory Board
- IR contact
The promotion with Stockhouse appears to have ended. ==> why do you think that and does it matter? Maybe they have replaced it with something else? something better ... something more effective ;) The stock is staganant. ==> as the market waits for the anticipated: - multiple data readouts
- multiple BD (business development) deals
- possible partnering of xB3-001
and then will react accordingly. The warrants have been extended and the exercise price reduced below $1. ==> a non-event and you can read more great commentary about it over here BTW you forgot to mention the great news that is found in the new corporate presentation that was released late yesterday and that is that the the timeline for the release of R&D data has been stated as Q1, 2021, for xB3-007 (ERT for Gaucher), xB3-004 (IL-1RA), xB3-007 (ERT for Parkinson’s and Lewy Body Dementia) and for xB3-Progranulin for Frontotemporal Dementia/ALS).: 
Of course you can read more about the new corporate presentation from someone who is very knowledgeable about the company, their technologies, and the BBB market over here